journal article·2024-09-02

Hierarchically Dual-Targeted Casein-Coated Iron Oxide Nanoparticles as Oral Thermal Agents for Noninvasive and Reversible Male Contraception

Weihua Ding, Zhichuan Chen, Chuxian Chen, Yayun Gu, Damin Yun, Sheng Gao, Fei Sun

ACS Materials Letters· Volume 6· Issue 9
Publisher page

Abstract

Mild testicular hyperthermia holds promise as a contraceptive approach. However, the great challenge lies in developing well-tolerated and highly targeted methods for testicular hyperthermia. Here, we engineered dual-targeted casein (CN) coated magnetic iron oxide nanoparticles as oral thermal agents for male contraception. The core Fe 3 O 4, facilitating magnetic targeting and magnetic hyperthermia, was conjugated with anti-luteinizing hormone receptor (anti-LHR) by initial H 2 N-PEG-NH 2 modification and then coated with CN in a layer-by-layer fashion (MNs@LC). MNs@LC exhibited remarkable stability in the gastric environment after oral administration under magnetic guidance. Upon reaching the intestine, enzymatic cleavage of casein exposed the anti-LHR, enabling active targeting and increased cellular uptake. In vivo investigations validated the improved accumulation of the dual-targeted system in the testis, allowing for high heating efficiency under an alternating magnetic field and ultimately achieving noninvasive and reversible contraception. This approach offers a fresh perspective on creating dual-targeted platforms for oral delivery strategies.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Sperm and Testicular Function · Iron Metabolism and Disorders

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Medical School, Institute of Reproductive Medicine, Nantong University, Nantong 226001, Jiangsu, People’s Republic of China

Department of Anesthesiology, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou 225000, Jiangsu, People’s Republic of China

Funding

National Key Research and Development Program of China · Key Research and Development Program of Ningxia · Key Research and Development Program of Zhejiang Province · National Natural Science Foundation of China

References (61)

Show source-provided references
1. 10.1177/155798831559636110.1177/1557988315596361 ↗
2. 10.1530/REP-08-003610.1530/REP-08-0036 ↗
3. 10.1016/j.theriogenology.2020.08.03410.1016/j.theriogenology.2020.08.034 ↗
4. 10.1186/s12610-016-0047-210.1186/s12610-016-0047-2 ↗
5. 10.1021/pr060073310.1021/pr0600733 ↗
6. Shafik A. · Adv. Contracept. Delivery Syst. · 1991 · 7 · 269
7. 10.1016/0010-7824(75)90109-210.1016/0010-7824(75)90109-2 ↗
8. 10.1021/nl400536d10.1021/nl400536d ↗
9. 10.1021/acsnano.5b0438010.1021/acsnano.5b04380 ↗
10. 10.1002/adma.20140250910.1002/adma.201402509 ↗
11. 10.1021/nn403202w10.1021/nn403202w ↗
12. 10.1177/109158181246596910.1177/1091581812465969 ↗
13. 10.1016/j.drudis.2019.09.02010.1016/j.drudis.2019.09.020 ↗
14. 10.1016/j.ijpharm.2020.11947210.1016/j.ijpharm.2020.119472 ↗
15. 10.1016/j.actbio.2021.01.02810.1016/j.actbio.2021.01.028 ↗
16. 10.1021/acsnano.5b0724910.1021/acsnano.5b07249 ↗
17. 10.1021/acs.chemrev.5b0011210.1021/acs.chemrev.5b00112 ↗
18. 10.3390/pharmaceutics1309146510.3390/pharmaceutics13091465 ↗
19. 10.1016/j.actbio.2019.07.01710.1016/j.actbio.2019.07.017 ↗
20. 10.1039/c0jm00994f10.1039/c0jm00994f ↗
21. 10.1088/0957-4484/25/45/45200110.1088/0957-4484/25/45/452001 ↗
22. 10.1080/0265673080210475710.1080/02656730802104757 ↗
23. 10.1021/acs.nanolett.1c0218110.1021/acs.nanolett.1c02181 ↗
24. 10.1021/acsnano.8b0047010.1021/acsnano.8b00470 ↗
25. 10.1021/acsami.7b1652410.1021/acsami.7b16524 ↗
26. 10.1016/j.jconrel.2013.04.02010.1016/j.jconrel.2013.04.020 ↗
27. 10.1016/j.addr.2013.01.00310.1016/j.addr.2013.01.003 ↗
28. 10.1016/j.addr.2013.02.00210.1016/j.addr.2013.02.002 ↗
29. 10.1016/j.jconrel.2013.03.02910.1016/j.jconrel.2013.03.029 ↗
30. 10.7150/thno.1368610.7150/thno.13686 ↗
31. 10.1016/j.biomaterials.2017.10.04810.1016/j.biomaterials.2017.10.048 ↗
32. 10.1038/nmat177510.1038/nmat1775 ↗
33. 10.1002/adma.20160164310.1002/adma.201601643 ↗
34. 10.1021/nl401952h10.1021/nl401952h ↗
35. 10.1002/anie.20090156610.1002/anie.200901566 ↗
36. 10.1021/acsnano.7b0495510.1021/acsnano.7b04955 ↗
37. 10.1021/acsnano.9b0089210.1021/acsnano.9b00892 ↗
38. 10.1016/j.theriogenology.2016.08.03010.1016/j.theriogenology.2016.08.030 ↗
39. 10.1071/RD1502710.1071/RD15027 ↗
40. 10.1095/biolreprod.105.04347110.1095/biolreprod.105.043471 ↗
41. 10.1016/j.biomaterials.2014.10.05910.1016/j.biomaterials.2014.10.059 ↗
42. 10.1021/am400713j10.1021/am400713j ↗
43. 10.1016/j.jmmm.2010.09.00910.1016/j.jmmm.2010.09.009 ↗
44. 10.1039/D4NR00104D10.1039/D4NR00104D ↗
45. 10.1021/acsami.1c1232310.1021/acsami.1c12323 ↗
46. 10.1039/C4NR06239F10.1039/C4NR06239F ↗
47. 10.1016/j.jmmm.2018.03.06510.1016/j.jmmm.2018.03.065 ↗
48. 10.1016/j.jssc.2011.12.01110.1016/j.jssc.2011.12.011 ↗
49. 10.1016/j.jmmm.2023.17081710.1016/j.jmmm.2023.170817 ↗
50. 10.1039/C9NR00498J10.1039/C9NR00498J ↗
51. 10.3390/nano1103062710.3390/nano11030627 ↗
52. 10.1039/D1NA00478F10.1039/D1NA00478F ↗
53. 10.1080/17435390.2020.184293410.1080/17435390.2020.1842934 ↗
54. 10.1007/s11095-010-0291-710.1007/s11095-010-0291-7 ↗
55. 10.1021/mp300649z10.1021/mp300649z ↗
56. 10.1002/j.1939-4640.1997.tb01896.x10.1002/j.1939-4640.1997.tb01896.x ↗
57. 10.1038/s41586-024-07336-w10.1038/s41586-024-07336-w ↗
58. 10.4149/BLL_2015_05110.4149/BLL_2015_051 ↗
59. 10.1016/j.pbiomolbio.2017.10.00110.1016/j.pbiomolbio.2017.10.001 ↗
60. 10.1016/j.biomaterials.2016.03.02610.1016/j.biomaterials.2016.03.026 ↗
61. 10.3390/ani1003038410.3390/ani10030384 ↗